Get the Stockscreener App
4.90
1.21%
-0.06
Optimi Health Corp stock is traded at $4.90, with a volume of 26,712.
It is down -1.21% in the last 24 hours and down -1.61% over the past month.
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
See More
Previous Close:
$4.96
Open:
$4.93
24h Volume:
26,712
Relative Volume:
0.45
Market Cap:
$28.06M
Revenue:
$257.00K
Net Income/Loss:
$-3.07M
P/E Ratio:
-5.1433
EPS:
-0.9527
Net Cash Flow:
$-1.40M
1W Performance:
-1.21%
1M Performance:
-1.61%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.76
$4.93
1-Week Range:
$4.73
$5.15
52-Week Range:
$4.00
$6.20
Optimi Health Corp Stock (OPTH) Company Profile
Compare OPTH vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPTH
Optimi Health Corp
|
4.90 | 28.06M | 257.00K | -3.07M | -1.40M | -0.9527 |
TAK
Takeda Pharmaceutical Co Adr
|
18.59 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.22 | 46.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
70.27 | 29.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
472.21 | 20.25B | 3.17B | 1.29B | 1.01B | 27.09 |
Optimi Health Corp Stock (OPTH) Latest News
Optimi Health releases 5 mg psilocybin batch for Canadian Phase 2 trial - Mugglehead Investment Magazine
Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial - marketscreener.com
Optimi completes psilocybin capsule batch for trial, Australia - Investing.com Australia
Optimi completes psilocybin capsule batch for trial, Australia By Investing.com - Investing.com UK
Optimi Health Completes Psilocybin Production for Health - GlobeNewswire
Optimi Health Corp. (OPTI.CN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer to Advance Psilocybin and MDMA Trials - kalkine.ca
Optimi Health Appoints Dr Michael Blough to Head Clinical Development - Yahoo Finance
Optimi Health appoints Michael Blough as clinical officer - Investing.com
Optimi Health Corp. Appoints Michael Blough as Chief Clinical Development Officer to Advance Psychedelic Clinical Trials - Quiver Quantitative
Psychedelic depression and PTSD trials get new lead at Optimi Health (OPTH) - Stock Titan
Optimi Health (OPTI.CN) Names Dr. Michael Blough Chief Clinical Development Officer to Lead Psilocybin and MDMA Trial Programme - kalkine.ca
Optimi Health Corp. Common Shares (NASDAQ: OPTH) Stock Price, News & Analysis - kalkine.com.au
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial - Yahoo Finance
Optimi Health2026 Funding Rounds & List of Investors - Tracxn
Optimi Health Stock Slips 4.17%: Controlled Substances Commercialization Friction and Sector Volatility Weigh on Sentiment - kalkine.ca
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA T - Benzinga
SRx Health Decided To Invest In A Psychedelic Drug Company That Just Went Public – Here’s What Aided The Decision - Stocktwits
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder - Investing News Network
Optimi Health plans phase 3 MDMA trial for PTSD in Canada - Investing.com Australia
Optimi Health Launches Phase 3 MDMA-Assisted Therapy Trial for PTSD Targeting Veterans and Frontline Workers - kalkine.ca
Optimi Health (OPTH) lines up Phase 3 MDMA PTSD trial for veterans - Stock Titan
Optimi Health (OPTI.CN) Launches Health Canada-Authorized Phase 3 MDMA Trial for PTSD in Veterans and Frontline Workers - kalkine.ca
Optimi Health (OPTH) Stock Price, News & Analysis - Stock Titan
3 Small Cap Stocks With Strong Revenue Growth And Low Debt - Yahoo Finance
Optimi Health Corp. (CN:OPTI) Gains Momentum as Psychedelic Medicine Expansion and Clinical Progress Improve Investor Outlook - kalkine.ca
Optimi Health Corp Share PriceOPTI, RNS News, Articles, Quotes, & Charts (CNSX:OPTI) - Proactive financial news
OPTI: Commercially supplying natural psychedelics, expanding globally as regulations advance - TradingView
Optimi Health at H.C. Wainwright conference: early lead in psychedelics - Investing.com
OPTI: Commercial psychedelic manufacturer expands globally as regulatory momentum accelerates - TradingView
Optimi Health Corp. (CN:OPTI) Advances as Psychedelic Medicine Pipeline and Clinical Expansion Improve Investor Sentiment - kalkine.ca
Optimi Health plans phase 2 psilocybin trial for depression By Investing.com - Investing.com Nigeria
OPTH Stock Price, Quote & News - Syfe
OPTH Looks 64.2% Overvalued on GF Value™ - GuruFocus
Optimi Health Launches Health Canada-Authorized Phase 2 Psilocybin Trial for Major Depressive Disorder - kalkine.ca
Optimi Health To Initiate Phase 2 Psilocybin Trial For Major Depression - RTTNews
Optimi Health plans phase 2 psilocybin trial for depression - Investing.com
Optimi Health CorpTrial Initiation Planned For H1 2027, Dosing To Complete By End Of 2027 - TradingView
Optimi Health Announces Health Canada-Authorized Phase 2 Trial of Natural Psilocybin for Major Depressive Disorder - Quiver Quantitative
A 200-person psilocybin depression trial is coming from Optimi Health (OPTH); here’s when and where - Stock Titan
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder - Yahoo Finance
Optimi Health Stock Under Pressure: Can Psychedelic Growth Overcome Rising Execution and Funding Risks? - kalkine.ca
symbol__ Stock Quote Price and Forecast - CNN
Optimi Health to Present at H.C. Wainwright Global Investment Conference - TipRanks
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Optimi Health Corp. to Present at H.C. Wainwright 28th Annual Global Investment Conference in September 2026 - kalkine.ca
Psychedelic-drug maker Optimi Health (OPTH) plans investor meetings in New York - Stock Titan
Optimi Health Stock Faces Renewed Pressure as Psychedelic-Sector Sentiment Weakens - kalkine.ca
Optimi Health (CN:OPTI) Drops 4.12% as Revenue Weakness, Funding Risk and Psychedelic-Sector Uncertainty Pressure Sentiment - kalkine.ca
Optimi Health Corp (CN: OPTI) Share Price, OPTI Stock News, OPTI Share Price & Updates - kalkine.ca
Optimi Health (OPTH) lines up discounted share funding with new $100M facility - Stock Titan
Optimi Health Corp Stock (OPTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.46%
0.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):